Strategic partnerships Potential sales opportunities with aerospace and defense sectors given Boeing's previous licensing collaboration for 222nm sanitization in flight decks and interiors. Target aerospace suppliers, aircraft OEMs, and DOD/DoD contractors for onboard disinfection solutions in occupied cabins and crew areas.

Occupied space safety Markets with high occupant density such as commercial aircraft, airports, hospitals, offices, and transit hubs are prime targets for autonomous 222nm disinfection devices that operate in occupied spaces, offering continuous pathogen mitigation beyond traditional cleaning.

Early funding traction Recent venture funding and NASA/Air Force SBIR heritage suggest credibility and growth potential. Leverage investor traction in outreach to strategic investors, channel partners, and customers seeking validated, mission-critical disinfection technology.

Financial scale Revenue in the mid-range of tens of millions and a modest funding cushion indicate a growing SMB-to-Mid-market footprint. Focus on multi-unit deployments, maintenance contracts, and integration with existing IAQ (indoor air quality) systems to drive higher ticket opportunities.

Global quality edge NASA and Air Force-backed validation plus a global disinfection capability position Far UV as a premium safety technology. Position to property managers, healthcare operators, and large facilities managers seeking robust, validated pathogen control in occupied environments.